Amneal Reports Third Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Amneal Pharmaceuticals (AMRX) Misses Q3 EPS by 5c; Offers FY22 Guidance
November 4, 2022 6:02 AM EDTAmneal Pharmaceuticals (: AMRX) reported Q3 EPS of $0.14, $0.05 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $546 million versus the consensus estimate of $564.24 million.
GUIDANCE:
Amneal Pharmaceuticals sees FY2022 EPS of $0.65-$0.70, versus the consensus of $0.68. Amneal... More
